<h4>Background</h4>Mineralocorticoid receptor antagonists (MRAs) are often empirically used for patients with low-renin hypertension (LRH) or probable primary aldosteronism (PA) who decline surgery. The gene discussed is NR3C2; the disease is Hypertension.